Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
BMJ Evidence-Based Medicine
|
July 20, 2021
Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review
Iain Crossingham, Sally Turner, Sanjay Ramakrishnan, et al.
The Lancet. Respiratory Medicine
|
April 10, 2022
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
April 12, 2026
Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)
Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan, et al.
The Lancet. Respiratory Medicine
|
November 30, 2024
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Sanjay Ramakrishnan, Richard E K Russell, Hafiz R Mahmood, et al.
ERJ Open Research
|
July 5, 2023
Patients' acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration-European Lung Foundation online patient survey
Iwein Gyselinck, Sanjay Ramakrishnan, Kristina Vermeersch, et al.
ERJ Open Research
|
May 15, 2024
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19
Steven P Cass, Dan V Nicolau, Jonathan R Baker, et al.
The Lancet. Respiratory Medicine
|
November 4, 2023
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial
Sanjay Ramakrishnan, Helen Jeffers, Beverly Langford-Wiley, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 24, 2021
Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus
Sanjay Ramakrishnan, Wim Janssens, Pierre-Regis Burgel, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 8, 2025
Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report
Raja Dhar, Sanjay Ramakrishnan, Parvaiz A Koul, et al.
The Lancet. Respiratory Medicine
|
April 12, 2021
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Sanjay Ramakrishnan, Dan V Nicolau, Beverly Langford, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
BMJ Evidence-Based Medicine
|
July 20, 2021
Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review
Iain Crossingham, Sally Turner, Sanjay Ramakrishnan, et al.
The Lancet. Respiratory Medicine
|
April 10, 2022
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
April 12, 2026
Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)
Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan, et al.
The Lancet. Respiratory Medicine
|
November 30, 2024
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Sanjay Ramakrishnan, Richard E K Russell, Hafiz R Mahmood, et al.
ERJ Open Research
|
July 5, 2023
Patients' acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration-European Lung Foundation online patient survey
Iwein Gyselinck, Sanjay Ramakrishnan, Kristina Vermeersch, et al.
ERJ Open Research
|
May 15, 2024
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19
Steven P Cass, Dan V Nicolau, Jonathan R Baker, et al.
The Lancet. Respiratory Medicine
|
November 4, 2023
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial
Sanjay Ramakrishnan, Helen Jeffers, Beverly Langford-Wiley, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 24, 2021
Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus
Sanjay Ramakrishnan, Wim Janssens, Pierre-Regis Burgel, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 8, 2025
Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report
Raja Dhar, Sanjay Ramakrishnan, Parvaiz A Koul, et al.
The Lancet. Respiratory Medicine
|
April 12, 2021
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Sanjay Ramakrishnan, Dan V Nicolau, Beverly Langford, et al.
Page
of 3